Evaluating Hepatic Arterial vs. Intravenous Adabrelimab Combined with Bevacizumab and Hepatic Artery FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2026-09-25
76
Participants Needed
3
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Adabrelimab given either through hepatic arterial infusion or intravenous infusion, combined with hepatic artery FOLFOX chemotherapy and intravenous Bevacizumab as a first-line treatment for advanced hepatocellular carcinoma HCC. This phase II trial compares two methods of administering Adabrelimab to see which works better in treating this serious liver cancer stage. The study is motivated by previous findings suggesting that delivering anti-PD-L1 therapy directly to the liver might improve response rates.
Participants are randomly assigned to one of two groups one receives hepatic arterial infusion of Adabrelimab plus intravenous Bevacizumab and hepatic artery infusion chemotherapy with the FOLFOX regimen the other receives intravenous Adabrelimab with the same Bevacizumab and chemotherapy treatments. Both groups undergo up to six cycles of this triple combination treatment before continuing with intravenous Adabrelimab and Bevacizumab for maintenance until disease progression or unacceptable side effects occur.
During the study, participants will have tumor imaging every six weeks to assess response, along with regular monitoring for safety and side effects. Researchers will measure outcomes such as objective response rate, progression-free survival, overall survival, and duration of response over a 36-month period. Laboratory tests and clinical evaluations will ensure participants maintain adequate organ function and performance status. The total study duration extends until December 2028, with active treatment and follow-up for disease progression and adverse events.
CONDITIONS
Brief Title
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Research Team
L
Lujun Shen, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Voluntarily agree to participate and sign informed consent
Age 18 years or older at consent
Diagnosis of hepatocellular carcinoma by clinical or pathological methods
Barcelona Clinic Liver Cancer stage C with vascular or bile duct invasion or distant metastasis (excluding Vp4 tumor thrombus)
No prior systemic therapy for HCC or progression/residual after prior local therapy with at least 1 month since last local treatment
ECOG performance status of 0-1 and Child-Pugh grade A or B with score 7
No history of autoimmune disease
Expected survival of at least 3 months
At least one measurable lesion per RECIST v1.1 criteria
Adequate blood counts and liver/renal function within one week before enrollment
Women of childbearing potential must have negative pregnancy test and agree to contraception; men must agree to contraception during and six months after study
You will not qualify if you...
Allergy to iodine contrast agents preventing hepatic arterial infusion chemotherapy
Use of immunosuppressants or systemic corticosteroids for immunosuppression within 1 month before randomization
Active infections not controlled effectively
Severe or untreated gastroesophageal varices with bleeding risk
Brain or bone metastases needing urgent treatment
Pregnant, suspected pregnant, or breastfeeding
Use of certain platelet-affecting drugs within 10 days before starting study treatment
Thrombotic or embolic events within 6 months before study treatment start
Congenital or acquired immunodeficiency
History of other malignant tumors
Myocardial infarction, severe angina, or congestive heart failure within 12 months before study
Renal failure requiring dialysis
History of organ transplantation
Severe acute or chronic illness or lab abnormalities increasing study risks or interfering with results
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 36 months
Participants receive either hepatic arterial infusion or intravenous infusion of Adabrelimab combined with intravenous Bevacizumab and hepatic artery infusion chemotherapy with the FOLFOX regimen. The triple combination is given for up to 6 cycles, followed by intravenous maintenance therapy until disease progression or unacceptable toxicity.
Tumor imaging assessments every 6 weeks
Follow-up
Duration - Up to 36 months
Participants are monitored for disease progression, overall survival, and treatment safety for up to 36 months after starting treatment.
Regular clinical and laboratory assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Super Hi-TCR-T Cells Targeting Multiple Markers for Treating Advanced Liver Cancer and Other Solid Tumors
Phase 2 Study of Immunotherapy With or Without Particle Beam Radiation Therapy for Advanced Hepatocellular Carcinoma with Vascular Invasion
Study of CG-102-12C CAR-T Cell Therapy for Adults With Glypican-3 Positive Advanced Hepatocellular Carcinoma Who Have Had Previous Treatments
Phase I Trial of Super CAR-T Cell Therapy Targeting GPC3 for Advanced Liver Cancer Hepatocellular Carcinoma
Study of Personalized Neoantigen-Specific T-Cell Therapy for Advanced Liver Cancer in Adults Aged 18 to 75
Observing Different First-Line Immunotherapy Treatments in Adults with Advanced Liver Cancer and Their Effects on Immune Response
Phase 12 Study of Dual-Target GPC3 and B7-H3 CAR-NK Cell Therapy for Adults with Advanced or Metastatic Hepatocellular Carcinoma
Evaluating Hepatic Arterial vs. Intravenous Adabrelimab Combined with Bevacizumab and Hepatic Artery FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma
Study of Personalized Tumor Neoantigen mRNA Therapy Combined With PD-1 and Anti-VEGFR Antibodies Plus TACE for Advanced Hepatocellular Carcinoma in Adults
Open-Label Study of WGI-0301 with Sorafenib Compared to Sorafenib Alone in Adults with Advanced Hepatocellular Carcinoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial.